Biochemical and psychophysiological effects of augmenting serotonergic and noradrenergic function were compared in 12 normal volunteers. Fluvoxamine (100 mg), a serotonin (5-HT) re-uptake inhibitor, maprotiline (75 mg), a noradrenaline re-uptake inhibitor, and placebo were given for 7 days each to each subject. Subjects were tested pre-drug on days 1, 4 and 8 of each treatment. Catecholamines in 24 h urine, 'platelet-rich' plasma 5-HT and hormones, EEG, auditory evoked response, skin conductance, and bodily and psychological responses were monitored. Augmentation of central 5-HT by fluvoxamine was demonstrated by the decrease of 5-HT plasma levels. Fluvoxamine also reduced urinary dopamine, indicating a decrease in dopamine metabolism in response to augmentation of 5-HT function. Decrease in pulse rate, loss of appetite and a mild arousing effect were also detected with administration of fluvoxamine. Thus, further investigations on the neuro chemistry of anxiety disorders should include the study of mechanisms of interaction of neurotransmitters.
Abelson J.L., Glitz D., Cameron O.G., Lee M.A., Bronzo M., Curtis G.C. (1991) Blunted growth hormone response to clonidine in patients with generalized anxiety disorder. Arch Gen Psychiatr48: 157-162
2.
Agren H., Mefford I.N., Rudorfer M.V., Linnoila M., Potter W.Z. (1986) Interacting neurotransmitter systems. A non-experimental approach to the 5HIAA-HVA correlation in human CSF. J Psychiatr Res20: 175-193
3.
Amin F., Davidson M., Davis K.L. (1992) Homovanillic acid measurement in clinical research: a review of methodology. Schizophrenia Bull18: 123-148
Baldwin D., Fineberg N., Montgomery S. (1991) Fluoxetine, fluvoxamine and extrapyramidal tract disorders. Int Clin Psychopharmacol6: 51-58
6.
Benfield P., Ward A. ( 1986) Fluvoxamine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness: Drugs32: 313-334
7.
Bond A.J., Lader M. (1974) The use of analogue scales in rating subjective feelings. Br J Clin Pharmacol9: 83-90
8.
Budman C.L., Brunn R.D. (1991) Persistent dyskinesia in a patient receiving fluoxetine . Am J Psychiatr148: 1403
9.
Carboni E., Di Chiara G. (1989) Serotonin release estimated by transcortical dialysis in freely-moving rats. Neuroscience32: 637-645
10.
Charney D.S., Woods S.W., Goodman W.K., Heninger G.R. (1987a) Neurobiological mechanisms of panic anxiety: biochemical and behavioral correlates of yohimbine-induced panic attacks. Am J Psychiatr144: 1030-1036
11.
Charney D.S., Woods S.W., Goodman W.K., Heninger G.R. (1987b) Serotonin function in anxiety. II. Effects of the serotonin agonist m-CPP in panic disorder patients and healthy subjects . Psychopharmacology92: 14-24
12.
Cooper J.R., Bloom F.E., Roth R.H. (1991) The biochemical basis of neuropharmacology. 3rd edn. Oxford University Press, Oxford
13.
Curran H.V., Lader M. (1986) The psychopharmacological effects of repeated doses of fluvoxamine, mianserine and placebo in healthy human subjects. Eur J Clin Pharmacol29: 601-607
14.
Deakin J F W (1993) A review of clinical efficacy of 5-HT1A agonists in anxiety and depression. J Psychopharmacol7: 283-289
15.
Deakin J F W, Graeff F.G. (1991) 5-HT and mechanisms of defence. J Psychopharmacol5: 305-315
16.
Degrell I., Nagy E. ( 1990) Correlations between cisternal CSF and plasma concentrations of HVA, MHPG, 5-HIAA, DA and NA. Biol Psychiatr27: 1179-1182
17.
Den Boer J.A., Westenberg H G M (1990) Serotonin function in panic disorder: a double blind placebo controlled study with fluvoxamine and ritanserin. Psychopharmacology102: 85-94
18.
Dratcu L., Lader M. (1993) Ansiedade: conceito, classificacão e biologia. Uma interpretação contemporânea da literatura. J Brasil Psiquiatr42: 19-32
19.
Fuxe K., Ogren SO, Agnati L.F., Benfenati F., Fredholm B., Andersson K., Zini I., Eneroth P. (1983) Chronic antidepressant treatment and central 5HT synapses. Neuropharmacology22: 389-400
20.
Geretsegger C., Böhmer F., Ludwig M. (1994) Paroxetine in the elderly depressed patient: randomized comparison with fluoxetine of efficacy, cognitive and behavioural effects . Int Clin Psychopharmacol9: 25-29
21.
Goodman W.K., McDougle C.J., Price L.H., Riddle M.A., Pauls D.L., Leckman J.F. (1990) Beyond the serotonin hypothesis: a role for dopamine in some forms of obsessive compulsive disorder? J Clin Psychiatr51 (Suppl 8): 36-43
22.
Gregory C.A., Anderson I.M., Cowen P.J. (1990) Metergoline abolishes the prolactin response to buspirone. Psychopharmacology100: 383-384
23.
Hockey R. (1978) Arousal and stress in human memory: some methodological and theoretical considerations. In Gruneber M M, Morris P E, Sykes R N (eds), Practical aspects of memory. Academic Press, London
24.
Hoeksema T., Goekoop J.G., Van Kempen G M J (1993) Effects of fluvoxamine on whole-blood serotonin and platelet number. J Clin Psychopharmacol13: 75-76
25.
Kahn R.S., Wetzler S. (1991) m-Chlorophenylpiperazine as a probe of serotonin function. Biol Psychiatr30: 1139-1166
26.
Kahn R.S., Van Praag H.M., Wetzler S., Asnis G., Barr G. ( 1988) Serotonin and anxiety revisited. Biol Psychiatr23: 189-208
27.
Karoum F., Korpi E.R., Linnoila M., Chuang L.W., Wyatt R.J. (1984) Reduced metabolism and turnover of rat brain dopamine, norepinephrine and serotonin by chronic desipramine and zimelidine treatments . Eur J Pharmacol100: 137-144
28.
Keating J., Dratcu L., Lader M., Sherwood R.A. (1993) Measurement of plasma serotonin by HPLC with electrochemical detection as an index of the in vivo activity of fluvoxamine. J Chromatogr Biomed Appl615: 237-242
29.
Klein D.F., Fink M.P. (1962) Psychiatric reaction patterns to imipramine. Am J Psychiatr119: 432-438
30.
Kosten T.R., Mason J.W., Giller E.L., Ostroff R.B., Harkness L. (1987) Sustained urinary norepinephrine and epinephrine elevation in post-traumatic stress disorder. Psychoneuroendocrinology12:13-20
31.
Kremer H P H, Goekoop J.G., Van Kempen G M J (1990) Clinical use of determination of serotonin in whole blood. J Clin Psychopharmacol10: 83-87
32.
Lee M.A., Cameron O.G., Gurguis G.N., Glitz D., Smith C.B., Hariharan M., Abelson J.L., Curtis G.C. (1990) Alpha 2-adrenoceptor status in obsessive-compulsive disorder. Biol Psychiatr27: 1083-1093
33.
McBride P.A., Tierney H., DeMeo M., Chen J.S., Mann J. ( 1990) Effects of age and gender on CNS serotonergic responsivity in normal adults. Biol Psychiatr27: 1143-1155
34.
McEntee W.J. (1992) On the role of serotonin in learning and memory . Eur Neuropsychopharmacol2: 184-185
35.
Meltzer H.Y., Nash J.F. (1991) Effects of antipsychotic drugs on serotonin receptors . Pharmacol Rev43: 587-604
36.
Moleman P. (1990) Effect of diet on urinary excretion of unconjugated catecholamines and some of their metabolites in healthy control subjects and depressed patients. Clin Chim Acta189: 19-24
37.
Murphy D.L., Zohar J., Benkelfat C., Pato M.T., Pigott T.A., Insel T.R. (1989) Obsessive compulsive disorder as a 5HT subsystem-related behavioural disorder. Br J Psychiatr155 (Suppl. 8): 15-24
38.
Murphy D.L., Lesch K.P., Aulakh C.S., Pigott T.A. (1991) Serotonin-selective arylpiperazines with neuroendocrine, behavioral, temperature and cardiovascular effects in humans. Pharmacol Rev43: 527-552
Nutt D., Lawson C. (1992) Panic attacks: a neurochemical overview of models and mechanisms. Br J Psychiatr160: 165-168
41.
Pinder R.M., Brogden R.N., Speight T.M., Avery G.S. (1977) Maprotiline. A review of its pharmacological properties and therapeutic efficacy in mental depressive states. Drugs13: 321-362
42.
Pitchot W., Ansseau M., Moreno A G., Hansenne, Frenckell R V. (1992) Dopaminergic function in panic disorder: comparison with major and minor depression . Biol Psychiatr32: 1004-1011
43.
Ramos R.T., Gentil V., Gorenstein C. (1993) Clomipramine and initial worsening in panic disorder: beyond the 'jitteriness syndrome'. J Psychopharmacol7: 265-269
44.
Saletu B., Grunberger J., Rajna P. (1983) Pharmaco-EEG profiles of antidepressants. Pharmacodynamic studies with fluvoxamine. Br J Clin Pharmacol15 (Suppl. 3): 369S-384S
45.
Salzman C., Jimerson D., Vasile R., Watsky E., Gerber J. (1993) Response to SSRI antidepressants correlates with reduction in plasma HVA: pilot study. Biol Psychiatr34: 569-571
46.
Southwick S.M., Krystal J.H., Morgan C.A., Johnson D., Nagy L.M., Nicolaou A., Heninger G.R., Charney D.S. (1993) Abnormal noradrenergic function in posttraumatic stress disorder. Arch Gen Psychiatr50: 266-274
47.
Sharma R.P., Javaid J.I., Faull K., Davis J.M., Janicack P.G. (1994) CSF and plasma MHPG, and the CSF MHPG index: pretreatment levels in diagnostic groups and response to somatic treatments. Psychiatr Res51: 51-60
48.
Spielberger C.D., Gorsuch R.L., Lushene R.E. (1970) The state-trait anxiety inventory. Consulting Psychologists Press, Palo Alto, CA
49.
Stahl S.M. (1985) Platelets as pharmacologic models for the receptors and biochemistry of monoaminergic neurons. In Longenecker G T (ed.), The platelets: physiology and pharmacology . Academic Press, Orlando, FL, pp. 307-340
50.
Stein M.H. (1991) Tardive dyskinesia in a patient taking haloperidol and fluoxetine. Am J Psychiatr148: 683
51.
Stephenson J.D. (1990) Neuropharmacological studies of the serotonergic system. Int Rev Psychiatr2: 157-178
52.
Uhde T., Stein M.B., Vittone B.J., Siever L.J., Boulenger J.P., Klein E., Mellman T.A. (1989) Behavioural and physiological effects of short-term and long-term administration of clonidine in panic disorder. Arch Gen Psychiatr46: 170-177
53.
Van Praag H.M., Lemus C., Kahn R. ( 1987) Hormonal probes of central serotonergic activity: do they really exist? Biol Psychiatr22: 86-98
54.
Warrington S.J. (1992) Clinical implications of the pharmacology of serotonin reuptake inhibitors. Int Clin Psychopharmacol7 (Suppl. 2): 13-19
55.
Zahn T.P. (1986) Psychophysiological approaches to psychophathology . In Coles G H, Donchin E, Porges S W (eds), Psychophysiology. Systems, processes, and applications. Elsevier, Oxford, pp. 508-610
56.
Zifa E., Fillion G. (1992) 5-Hydroxytryptamine receptors. Pharmacol Rev44: 401-458
